Eli Lilly's newest weight-loss drug relieved pain in patients with knee osteoarthritisMarket Watch • 12/11/25
Danish weight loss drug maker outlines ambitious 2030 strategy, ramping up pressure on Novo, LillyCNBC • 12/11/25
Lilly's next-gen drug tops Zepbound on weight loss in late-stage osteoarthritis trialReuters • 12/11/25
Eli Lilly's next-generation obesity drug delivers strong weight loss, reduces knee pain in late-stage trialCNBC • 12/11/25
Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trialPRNewsWire • 12/11/25
Eli Lilly's Weight-Loss Drugs Drove Its Stock Higher This Year. A New Plant in Alabama Could Boost ProductionInvestopedia • 12/10/25
Eli Lilly to build $6 billion manufacturing plant in Alabama to help make upcoming obesity pill, other drugsCNBC • 12/09/25
Lilly to build $6 billion facility to manufacture active pharmaceutical ingredients in AlabamaPRNewsWire • 12/09/25
Prediction: This Surprising Growth Stock Will Reach -- and Stay in -- the Trillion-Dollar Club in 2026.The Motley Fool • 12/09/25
Lilly and Adverum announce expiration and completion of Adverum tender offer and acquisitionPRNewsWire • 12/09/25
Lilly's Jaypirca (pirtobrutinib) significantly improved progression-free survival, reducing the risk of progression or death by 80%, versus chemoimmunotherapy in patients with treatment-naïve CLL/SLLPRNewsWire • 12/09/25
Healthcare Relevancies Clashes With Premium Valuations For Direxion's LLY-Focused ELIL, ELIS ETFsBenzinga • 12/08/25